 |
 |
||
 |
 |
 |
|
|
Skip To Content | ||||||
|
|||||||
|
|
 Application Information
|
|
Application Deadline |
Applications are due by May 1, 2007. |
|
Intergovernmental Review |
Letters from State Single Point of Contact (SPOC) are due no later than 60 days after application deadline. |
|
Public Health System Impact Statement (PHSIS)/Single State Agency Coordination |
Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline. |
The Substance Abuse and Mental Health Services Administration, Center for Substance Abuse
Treatment is accepting applications for fiscal year (FY) 2007 for the Physician Clinical Support
System for the Treatment of Substance Use Disorders (PCSS) cooperative agreement. The purpose of this program is to enhance and further develop the current DATA Physician Clinical Support System designed to assist physicians in treating patients dependent on heroin or prescription opioid drugs with FDA approved products containing buprenorphine.
The current SAMHSA-funded PCSS is supported by over 70 mentors, 5 clinical experts and a medical director. The target population for the clinical support system includes primary care physicians, pain specialists, psychiatrists and other non-addiction medical practitioners who treat opioid dependent patients and are less familiar withopioid dependence treatment than addictions specialists. However, addictions specialists will also be encouraged to participate in the PCSS or serve as mentors for physicians desiring to treat opioid dependent patients with
buprenorphine products.
PCSS is one of SAMHSA’s infrastructure programs. SAMHSA’s Infrastructure Grants support an array of activities to help the grantee build a solid foundation for delivering and sustaining effective substance abuse prevention and/or treatment and/or mental health services. Awardees may pursue diverse strategies and methods to achieve their infrastructure development and capacity expansion goals. The plan put forward in the grant application must show the linkages among needs, the proposed infrastructure development strategy, and increased system capacity that will enhance and sustain effective programs and services.
PCSS cooperative agreements are authorized under Section 509 of the Public Health Service Act, as amended. This announcement addresses the Drug Addiction Treatment Act of 2000, as amended by the Office of National Drug Control Policy Reauthorization Act of 2006 (Public Law 109-469), hereafter referred to as DATA, and Healthy People 2010 focus area 26 (Substance Abuse).
Eligibility is limited to the national professional medical organizations authorized by the Drug
Addiction Treatment Act of 2000 (DATA) to carry out the training of physicians desiring to
prescribe and/or dispense FDA approved buprenorphine products for the treatment of addictive
disorders. These are the American Society of Addiction Medicine, the American Academy
of Addiction Psychiatry, the American Medical Association, the American Osteopathic
Association, and the American Psychiatric Association. Any of these entities may apply
individually; they may also apply as a consortium comprised of all or several of the eligible
organizations. If a consortium is formed for this purpose, a single organization in the
consortium must be the legal applicant, the recipient of the award, and the entity legally
responsible for satisfying the grant requirements. If a consortium submits an application, the
application must include a written agreement outlining the roles and responsibilities of each
participating national professional medical organization. This agreement must be signed by an
authorized official of each member of the consortium and attached to the application in
Appendix 4 of the RFA, “Roles and Responsibilities of Participating National Professional Medical
Organizations.”
| Funding Mechanism: | Cooperative Agreement |
| Anticipated Total Available Funding: | $500,000 |
| Anticipated Number of Awards: | 1 |
| Anticipated Award Amount: |
Up to $500,000 |
| Length of Project Period: | Up to 3 years |
Proposed budgets cannot exceed $500,000 in total costs (direct and indirect) in any year of the proposed project. Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, and timely submission of required data and reports.
For questions on program issues, contact:
Anton C. Bizzell, M.D.
Medical Officer
Division of Pharmacologic Therapies
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Room 2-1067
Rockville, Maryland 20857
240-276-2702
anton.bizzell@samhsa.hhs.gov
For questions on grants management issues, contact:
Kimberly Pendleton
Office of Program Services, Division of Grants Management
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road, Room 7-1097
Rockville, MD 20857
(240) 276-1421
kimberly.pendleton@samhsa.hhs.gov
Applications that are not submitted on the required application form will be screened out and will not be reviewed.
Download the complete Announcement No. TI-07-007
Download RFA in MS Word format
Download RFA in Adobe PDF format
PHS 5161-1 (revised July 2000): Includes the face page, budget forms and checklist.
For further information on the forms and the application process, see Useful Information for Applicants
Additional materials available on this website include:
 |
|
|
Substance Abuse & Mental Health Services Administration • 1 Choke Cherry Road • Rockville, MD 20857
* Adobe™ PDF and MS Office™ formatted files require software viewer programs to properly read them. Click here to download these FREE programs now. |
||
